Publications in the past 5 years

Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.

Sourris KC, Ding Y, Maxwell SS, Al-Sharea A, Kantharidis P, Mohan M, Rosado CJ, Penfold SA, Haase C, Xu Y, Forbes JM, Crawford S, Ramm G, Harcourt BE, Jandeleit-Dahm K, Advani A, Murphy AJ, Timmermann DB, Karihaloo A, Knudsen LB, El-Osta A, Drucker DJ, Cooper ME, Coughlan MT.. Kidney International. 2024;105:132-149.

Minireview: Understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetes.

Kugathasan L, Sridhar VS, Tommerdahl KL, Xu C, Bjornstad P, Advani A, Cherney DZI. Metabolism. 2024;153:155785.

Interferons and interferon-related pathways in heart disease.

Tran DT, Batchu SN, Advani A. Frontiers in Cardiovascular Medicine. 2024;11:1354343.

Preventing occludin tight-junction disruption via inhibition of microRNA-193b-5p attenuates viral load and influenza-induced lung injury.

Vaswani CM, Varkouhi AK, Gupta S, Ektesabi AM, Tsoporis JN, Yousef S, Plant PJ, da Silva AL, Cen Y, Tseng YC, Batah SS, Fabro AT, Advani SL, Advani A, Leong-Poi H, Marshall JC, Garcia CC, Rocco PRM, Albaiceta GM, Sebastian-Bolz S, Watts TH, Moraes TJ, Capelozzi VL, Dos Santos CC. Molecular Therapy. 2023;31:2681-2701.

Altered expression, but small contribution, of the histone demethylase KDM6A in obstructive uropathy in mice.

Hong LYQ, Yeung ESH, Tran DT, Yerra VG, Kaur H, Kabir MDG, Advani SL, Liu Y, Batchu SN, Advani A. Disease Models & Mechanisms. 2023;16:dmm049991.

Pressure overload induces ISG15 to facilitate adverse ventricular remodeling and promote heart failure

Yerra VG, Batchu SN, Kaur H, Kabir MDG, Liu Y, Advani SL, Tran DT, Sadeghian S, Sedrak P, Billia F, Kuzmanov U, Gramolini AO, Qasrawi DO, Petrotchenko EV, Borchers CH, Connelly KA, Advani A. The Journal of Clinical Investigation. 2023;133:e161453.

Single cell G-protein coupled receptor profiling of Transcription factor 21 expressing activated kidney fibroblasts

Kaur H, Yerra VG, Batchu SN, Tran DT, Kabir MDG, Liu Y, Advani SL, Sedrak P, Geldenhuys L, Tennankore KK, Poyah P, Siddiqi FS, Advani A. British Journal of Pharmacology. 2023;133:Epub ahead of print April 28.

The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors.

Kugathasan L, Dubrofsky L, Advani A, Cherney DZI. Expert Reviews in Cardiovascular Therapy. 2023;21:15-34.

Sustained improvement in glycemic control in emerging adults with Type 1 diabetes 2 years after the start of the COVID-19 pandemic.

Swaich H, Advani A. Diabetes Therapy. 2023;14:153-165.

The SGLT2i dapagliflozin reduces RV mass independent of changes in RV pressure induced by pulmonary artery banding.

Connelly KA, Wu E, Visram A, Friedberg MK, Batchu SN, Yerra VG, Thai K, Nghiem L, Zhang Y, Kabir G, Desjardins JF, Advani A, Gilbert RE. Cardiovascular Drugs and Therapy. 2022; Epub ahead of print Sep 29.

DJ-1 binds to rubicon to impair LC-3 associated phagocytosis.

Gupta S, Amatullah H, Tsoporis JN, Wei K, Monteiro APT, Ektesabi AM, Varkouhi AK, Vaswani CM, Formosa A, Fabro AT, Batchu SN, Fjell C, Russell JA, Walley KR, Advani A, Parker TG, Marshall JC, Rocco PRM, Fairn GD, Mak TW, Dos Santos CC. Cell Death and Differentiation. 2022;29:2024-2033.

Role of CCR2-positive cardiac macrophages in pathological ventricular remodeling.

Yerra VG, Advani A. Biomedicines. 2022;10:661.

Perceptions and correlates of distress due to the COVID-19 pandemic and stress management strategies among people with diabetes: a mixed methods study.

Im J, Escudero C, Zhang K, Choi D, Sivakumar A, Booth GL, Sale J, Pritlove C, Advani A, Yu CH. Canadian Journal of Diabetes. 2022;46:253-261.

Empagliflozin disrupts a Tnfrsf12a-mediated feed forward loop trial that promotes left ventricular hypertrophy.

Yerra VG, Batchu SN, Kabir G, Advani SL, Liu Y, Siddiqi FS, Connelly KA, Advani A. Cardiovascular Drugs and Therapy. 2022;36:619-632

Lung and kidney ACE2 and TMPRSS2 in renin angiotensin system blocker treated comorbid diabetic mice mimicking host factors that have been linked to severe COVID-19.

Batchu SN, Kaur H, Yerra VG, Advani SL, Kabir MG, Liu Y, Klein T, Advani A. Diabetes. 2021;70:759-771.

Acute kidney injury: a bona fide complication of diabetes. Diabetes.

Advani A. Diabetes. 2020;69:2229-2237.

Experiences and perspectives of the parents of emerging adults living with type 1 diabetes.

Pritlove C, Markowitz B, Mukerji G, Advani A*, Parsons JA*. BMJ Open Diabetes Research and Care. 2020;e001125.

The dipeptidyl peptidase-4 inhibitor linagliptin directly enhances the contractile recovery of mouse hearts at a concentration equivalent to that achieved with standard dosing in humans.

Batchu SN, Yerra VG, Liu Y, Advani SL, Klein T, Advani A. IJMS 2020;21:E5757.

A common glomerular transcriptomic signature distinguishes diabetic kidney disease from other kidney diseases in humans and mice. Current Research in

Abdalla M, Abdalla M, Siddiqi FS, Geldenhuys L, Batchu SN, Tolosa MF, Yuen DA, Dos Santos CC, Advani A. Translational Medicine. 2020;S2452-3186:30034-30039.

Acute kidney injury: a bona fide complication of diabetes.

Advani A. Diabetes. 2020;69:2229-2237.

Experiences and perspectives of the parents of emerging adults living with type 1 diabetes.

Pritlove C, Markowitz B, Mukerji G, Advani A, Parsons JA. BMJ Open Diabetes Research and Care. 2020;8:e001125.

The dipeptidyl peptidase-4 inhibitor linagliptin directly enhances the contractile recovery of mouse hearts at a concentration equivalent to that achieved with standard dosing in humans.

Batchu SN, Yerra VG, Liu, Y, Advani SL, Klein T, Advani A. IJMS. 2020;21:E5757.

A common glomerular transcriptomic signature distinguishes diabetic kidney disease from other kidney diseases in humans and mice.

Abdalla M, Abdalla M, Siddiqi FS, Geldenhuys L, Batchu SN, Tolosa MF, Yuen DA, Dos Santos CC, Advani A. Current Research in Translational Medicine. 2020;S2452-3186:30034-30039.

Screening and treatment outcomes in adults and children With Type 1 Diabetes and asymptomatic celiac disease: The CD-DIET Study.

Mahmud FH, Clarke ABM, Joachim KC, Assor E, McDonald C, Saibil F, Lochnan HA, Punthakee Z, Parikh A, Advani A, Shah BR, Perkins BA, Zuijdwijk CS, Mack DR, Koltin D, De Melo EN, Hsieh E, Mukerji G, Gilbert J, Bax K, Lawson ML, Cino M, Beaton MD, Saloojee NA, Lou O, Gallego PH, Bercik P, Houlden RL, Aronson R, Kirsch SE, Paterson WG, Marcon MA. Diabetes Care. 2020;43:1553-1556.

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.

Connelly KA, Zhang Y, Desjardins JF, Ngheim L, Visram A, Batch SN, Yerra VG, Kabir G, Thai K, Advani A, Gilbert RE. Cardiovascular Diabetology. 2020;19:13.

The endothelial barrier is not rate-limiting to insulin action in the myocardium of male mice.

Sanwal R, Khosraviani N, Advani SL, Advani A, Lee WL. Endocrinology. 2020;161:bqaa029. Feb 27.

Positioning time in range in diabetes management.

Advani A. Diabetologia. 2020;63:242-252.

Dysregulated expression but redundant function of the long non-coding RNA HOTAIR in diabetic kidney disease.

Majumder S, Hadden MJ, Thieme K, Batchu SN, Niveditha D, Chowdhury S, Yerra VG, Advani SL, Bowskill BB, Liu Y, Vakili H, Alghamdi TA, White KE, Geldenhuys L, Siddiqi FS, Advani A. Diabetologia. 2019;62:2129-2142.

The 3i conceptual framework for recognizing patient perspectives of Type 1 diabetes during emerging adulthood.

Markowtiz B, Pritlove C, Mukerji G, Lavery JA, Parsons JA, Advani A. JAMA Network Open. 2019;2:e196944.

Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction.

Connelly KA, Zhang Y, Visram A, Advani A, Batchu SN, Desjardins JF, Thai K, Gilbert RE. JACC Basic to Translational Science. 2019;25:27-37.

Renal hemodynamic function and RAAS activation over the natural history of Type 1 diabetes.

Lytvyn Y, Bjornstad P, Lovshin JA, Boulet G, Farooqi MA, Lai V, Tse J, Cham L, Lovblom LE, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Advani A, Sochett E, Perkins BA, Cherney DZI. American Journal of Kidney Diseases. 2019;73:786-796.

Association between uric acid, renal hemodynamics and arterial stiffness over the natural history of type 1 diabetes.

Lytvyn Y, Bjornstad P, Lovshin JA, Singh SK, Boulet G, Farooqi MA, Lai V, Tse J, Cham L, Lovblom LE, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Advani A, Sochett E, Perkins BA, Cherney DZI. Diabetes, Obesity and Metabolism. 2019;21:1388-1398.